In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genentech options rights to Exelixis' XL518; exercised

Executive Summary

Genentech has signed a deal granting it options to globally develop Exelixis' (small-molecule therapeutics for cancer) XL518, for which Exelixis filed an IND just a few days before the alliance was announced. The candidate inhibits MEK (mitogen-activated protein kinase, MAPK), which plays a major role in the RAS/RAF/MEK/ERK pathway often activated in tumors.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Includes Contract
    • Co-Promotion
    • Trial Collaborations

Related Companies